IPO Details

Bidding Dates

14 Jul '25 - 16 Jul '25

Minimum Investment

₹14,820/ 1 Lot (26 Shares)

Price Range

₹540-₹570

Maximum Investment

₹1,92,660/ 13 Lot (338 Shares)

Retail Discount

To be announced

Issue Size

₹3,395.00

Investor category and sub category

Retail Individual Investors (RII)  |   Non-institutional Investors (NII)  |   Qualified Institutional Buyers (QIB)  |  

Anthem Biosciences IPO Important Dates

Important dates with respect to IPO allotment and listing

IPO Opening Date

Jul 14, 25

IPO Closing Date

Jul 16, 25

Basis of Allotment

Jul 17, 25

Initiation of Refunds

Jul 18, 25

IPO Listing Date

Jul 21, 25

About Anthem Biosciences IPO

The Anthem Biosciences IPO is a book-built issue valued at ₹3,395.00 crore, comprising a complete offer for sale of 5.96 crore equity shares. The IPO will open for public subscription on July 14, 2025, and close on July 16, 2025. The allotment of shares is likely to be finalised on July 17, 2025, with the tentative listing scheduled for July 21, 2025, on both the BSE and NSE.

The price band for the issue is fixed between ₹540 and ₹570 per share. Retail investors can apply for a minimum of one lot, which includes 26 shares and requires an investment of ₹14,040. For sNII (small non-institutional investors), the minimum application is 14 lots or 364 shares, costing ₹2,07,480, while bNII (big non-institutional investors) must apply for 68 lots or 1,768 shares, requiring ₹10,07,760.

JM Financial Limited is the lead manager for the IPO, and Kfin Technologies Limited is acting as the registrar. Investors should refer to the RHP for complete details.

Industry Outlook

  1. The global pharmaceutical market is set to grow from USD 1,450.6 billion in 2023 to USD 1,955.6 billion by 2028, at a CAGR of 6.2%. The innovator drug segment, which reached USD 737.1 billion in 2023, is projected to hit USD 1,046.2 billion by 2028 at a higher CAGR of 7.3%.
  2. India’s CRDMO sector, one of the fastest-growing globally, is expected to reach USD 14.1 billion by 2028, growing at 14.0% CAGR. This growth surpasses the global average of 9.0% and is driven by regulatory shifts like the US BIOSECURE Act. Anthem Biosciences, as a key player in the CRDMO space, is likely to benefit from this surge by attracting global pharma clients.
  3. Innovations like Flow Chemistry and Recombinant DNA are transforming pharmaceutical production. Anthem Biosciences, with expertise in these areas, standsto gain from the industry’s shift toward scalable, eco-friendly, and efficient manufacturing of complex molecules such as peptides and monoclonal antibodies.

Anthem Biosciences IPO Objectives

Anthem Biosciences Limited will not receive any proceeds from the Offer. All proceeds from the Offer, after deducting related expenses and applicable taxes, will be received by the selling shareholders.

About Anthem Biosciences Limited

Anthem Biosciences Limited is a technology-focused Contract Research, Development, and Manufacturing Organisation (CRDMO) with integrated operations across drug discovery, development, and commercial manufacturing.

Recognised as one of India’s few CRDMOs with both NCE (New Chemical Entity) and NBE (New Biological Entity) capabilities, the company serves a global clientele that includes emerging biotech firms and large pharmaceutical companies.

According to industry data, Anthem Biosciences became the fastest Indian CRDMO to reach ₹10,000 million in revenue within just 14 years, achieving this milestone in Fiscal 2021. It also recorded the highest revenue growth among peers in Fiscal 2023–24.

The company is known for its innovation across modalities such as RNAi, Antibody-Drug Conjugates (ADCs), peptides, lipids, and oligonucleotides. Manufacturing capabilities include custom synthesis, fermentation, flow chemistry, and biotransformation.

Its operations are split between CRDMO services and specialty ingredient manufacturing. The CRDMO arm supports end-to-end drug development, from target identification to commercial production. The specialty ingredients business produces fermentation-based APIs like enzymes and biosimilars, targeting regulated and semi-regulated markets.

These segments enhance Anthem’s global positioning and revenue potential.

How To Check the Allotment Status of Anthem Biosciences IPO?

Steps to check IPO allotment status on Angel One’s app:

  1. Log in to the Angel One app.
  2. Go to the IPO Section and then to IPO Orders.
  3. Select the individual IPO that you had appliedfor and check the allotment status.
  4. Angel One will notify you of your IPO allotment status via push notification and email.

How To Apply for the Anthem Biosciences IPO Online?

  1. Login to Your Angel One Account: Open the Angel One app or website and log in with your credentials.
  2. Locate the IPO Section: Navigate to the 'IPO' section on the platform.
  3. Select IPO: Find and select the Anthem Biosciences IPO from the list of open IPOs.
  4. Enter the Lot Size: Specify the number of lots you want to bid for.
  5. Submit Your UPI ID: Enter your UPI ID to link your payment method and submit your application.
  6. Approve Funds: Once you receive the bid request on your UPI app, approve it by entering your UPI PIN.

Contact Details of Anthem Biosciences IPO

Registered office: No. 49, F1 & F2, Canara Bank Road Bommasandra Industrial Area, Phase 1, Bommasandra, Bengaluru, Karnataka, 560099

Phone: +91 080 6672 400

E-mail: investors.abl@anthembio.com 

Anthem Biosciences IPO Reservation

Investor Category

Shares Offered

QIB Shares

Not more than 50.00% of the Net Offer

Retail Shares

Not less than 35.00% of the Net Offer

NII Shares

Not less than 15.00% of the Net Offer

Anthem Biosciences IPO Lot Size

Application

Lots

Shares

Amount

Retail (Min)

1

26

₹14,820

Retail (Max)

13

338

₹1,92,660

S-HNI (Min)

14

364

₹2,07,480

S-HNI (Max)

67

1,742

₹9,92,940

B-HNI (Min)

68

1,768

₹10,07,760

Anthem Biosciences IPO Promoter Holding

The promoters of the company include Ajay Bhardwaj, Ganesh Sambasivam, K Ravindra Chandrappa and Ishaan Bhardwaj.

Share Holding Pre-Issue

76.87%

Share Holding Post Issue&nbsp

74.68%

Note: Equity dilution will be determined by subtracting the Shareholding Post Issue from the Shareholding Pre Issue.

Key Performance Indicators for Anthem Biosciences IPO

KPI

Value

RoE (%)

20.04

RoCE (%)

26.88

RoNW (%)

20.82

EBITDA Margin (%)

36.81

PAT Margin(%)

23.38

Anthem Biosciences IPO Prospectus

Anthem Biosciences IPO Registrar and Lead Managers

Anthem Biosciences IPO Lead Managers

  • Jm Financial Limited

Registrar for Anthem Biosciences IPO

Kfin Technologies Limited

Anthem Biosciences IPO Registrar

Financial Performance of Anthem Biosciences Limited

Particulars Year ending on March 31, 2024 Year ending on March 31, 2023 Year ending on March 31, 2022
Revenue from Operation (in ₹ million) 14,193.70 10,569.24 12,312.56
Profit/ (loss) for the year (in ₹ million) 3673.10 3851.85 4,055.39
Earnings per Share (₹) 6.48 6.75 7.11
Net Worth (in ₹ million) 19,246.55 17,406.69 13,549.99
Return on Equity (%) 20.03 25.00 39.48
Current Ratio (x) 4.38 8.25 4.91
Total Borrowing (in ₹ million) 2,325.25 1,250.64 354.91

Know before investing

Strengths

8

  1. Fastest Indian CRDMO to cross ₹10,000 million revenue in 14 years.

  2. Offers integrated CRDMO services across both small molecules and biologics.

  3. Serves diverse global clients including Bayer AG and emerging biotech.

  4. Specialty ingredients contributed ₹3,362 million or 23.69% of FY24 revenue.

  5. Operating India’s largest fermentation capacity of 142 kL as of Sep 2024.

  6. Post-expansion, fermentation capacity to rise to 182 kL by H1 2025.

  7. Focused on high-growth niche segments like GLP-1 and biosimilars.

  8. Strong growth, profitability and capital efficiency from FY23 to FY24.

Risks

8

  1. CRDMO services contributed 81.13% revenue; demand decline may hurt.

  2. Development and manufacturing made up 73.06% revenue; risks persist.

  3. 86.80% revenue from FFS contracts; non-completion may reduce income.

  4. Top 10 customers contributed 76.75% revenue; loss impacts business.

  5. Regulatory non-compliance may disrupt exports, approvals, and customer confidence.

  6. Unit shutdowns or hazards may disrupt operations and impact revenue.

  7. Past fatalities and chemical risks pose safety and legal threats.

  8. Underused capacity and poor forecasts could hurt future performance.

  • How to Apply in IPO
  • How to Check IPO Allotment Status
Play Button

Login to Angel One App / Website & click on IPO

Select desired IPO & tap on "Apply"

Enter UPI ID, set quantity/price & submit

Accept mandate on the UPI app to complete the process

Play Button

Login to Angel One App / Website

Choose IPO section on Home Page

Click IPO Orders

Chose the IPO application you want to view the status for

Anthem Biosciences IPO Peer Comparison

Company Name EPS (Basic) NAV (per share) (₹) P/E (x) RoNW (%)
Anthem Biosciences Limited 6.48 34.43 - 20.03
Syngene International Limited 12.71 105.91 67.23 12.95
Sai Life Sciences Limited 4.57 53.83 168.94 8.89
Suven Life Sciences Limited 11.8 80.56 105.67 15.86
DIVI'S LABORATORIES Limited 60.27 511.21 97.03 12.15

Anthem Biosciences IPO FAQs

What is the Anthem Biosciences IPO?

Anthem Biosciences IPO is a book-built issue IPO. It runs from July 14, 2025, to July 16, 2025. 

When will the Anthem Biosciences IPO be allotted?

The Basis of Allotment will happen on Thursday, July 17, 2025. 

When will the Anthem Biosciences IPO open for subscription?

The IPO subscription window will open on July 14, 2025. 

What minimum lot size can retail investors subscribe to?

The minimum lot size retail investors can subscribe to is 1 lot, and the lot size is 26 shares for each lot. 

When will the Anthem Biosciences IPO list on exchanges?

The listing date for Anthem Biosciences IPO is Monday, July 21, 2025.

What is the issue size of the Anthem Biosciences IPO?

The issue size of the Anthem Biosciences IPO is ₹3,395.00 crore.

What are the open and close dates of the Anthem Biosciences IPO?

The open and close dates for Anthem Biosciences IPO are from July 14, 2025, to July 16, 2025.

What would be the listing gains on the Anthem Biosciences IPO?

Listing gains cannot be ascertained before the listing of the IPO on the stock exchange.

How to increase your chances of getting a Anthem Biosciences IPO allotment?

  1. Multiple Submissions: Use different Demat accounts to make multiple applications.
  2. Higher Price Band Bidding: Opt for bidding at the cut-off price or higher price band.
  3. Timely Subscription: Ensure you subscribe to the IPO within the specified time frame.

How do I approve the UPI mandate request for the Anthem Biosciences IPO?

You must complete the payment process by logging in to your UPI handle and approving the payment mandate.

Who is the registrar of Anthem Biosciences IPO?

Kfin Technologies Limited is the registrar responsible for managing the IPO allotment process and handling investor queries.

Where is the Anthem Biosciences IPO getting listed?

The Anthem Biosciences IPO is proposed to be listed on the Bombay Stock Exchange (BSE) and the National Stock Exchange (NSE).

Can I submit more than one application for the public issue of Anthem Biosciences IPO using one PAN?

You can submit only one application using your PAN card. 

How to read Anthem Biosciences Limited's financial statements?

To read Anthem Biosciences Limited’s financial statements, download the IPO’s RHP document. 

What is 'pre-apply' for the Anthem Biosciences IPO?

Pre-apply allows investors to apply for the Anthem Biosciences IPO two days before the subscription period opens, ensuring an early submission of your application. 

If I pre-apply for the Anthem Biosciences IPO, when will my order get placed?

Your order will be placed when the IPO opens for bidding, and a UPI request will follow within 24 hours. 

When will I know if my Anthem Biosciences IPO order is placed?

You will receive a notification once your order is successfully placed with the exchange after the bidding starts.